Quadrature Capital Ltd Purchases Shares of 32,392 BioMarin Pharmaceutical Inc. $BMRN

Quadrature Capital Ltd purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 32,392 shares of the biotechnology company’s stock, valued at approximately $1,780,000.

Other large investors have also modified their holdings of the company. Dodge & Cox raised its holdings in BioMarin Pharmaceutical by 1.4% in the 1st quarter. Dodge & Cox now owns 14,955,240 shares of the biotechnology company’s stock worth $1,057,186,000 after acquiring an additional 209,005 shares during the period. Geode Capital Management LLC grew its position in shares of BioMarin Pharmaceutical by 1.3% in the second quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company’s stock valued at $190,417,000 after purchasing an additional 43,185 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of BioMarin Pharmaceutical by 127.9% in the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock worth $203,987,000 after purchasing an additional 1,642,206 shares during the period. Nuveen LLC acquired a new position in shares of BioMarin Pharmaceutical during the 1st quarter worth about $184,475,000. Finally, Goldman Sachs Group Inc. lifted its position in shares of BioMarin Pharmaceutical by 212.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after purchasing an additional 1,083,512 shares during the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Stock Up 0.5%

BMRN opened at $55.79 on Friday. The company has a market capitalization of $10.72 billion, a P/E ratio of 20.97, a P/E/G ratio of 0.68 and a beta of 0.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.60. The firm’s fifty day moving average price is $53.80 and its two-hundred day moving average price is $56.09. BioMarin Pharmaceutical Inc. has a fifty-two week low of $50.76 and a fifty-two week high of $73.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.20). BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The business had revenue of $776.13 million for the quarter, compared to the consensus estimate of $782.42 million. During the same period in the previous year, the business posted $0.91 earnings per share. BioMarin Pharmaceutical’s revenue was up 4.1% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. On average, analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Sanford C. Bernstein dropped their price target on BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating on the stock in a research report on Monday, November 3rd. Barclays lowered their price objective on shares of BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 28th. Guggenheim upped their target price on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $66.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Finally, Wall Street Zen downgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Sixteen analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $89.91.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.